ODC1 and breast cancer: Several drugs targeting ODC1, including DFMO, PG‐11047, and SBP‐101 are under clinical trials for the treatment of breast cancer or other solid tumors.[29, 41] It is noteworthy that our data have demonstrated that genetic or pharmacological inhibition of ODC1 significantly suppresses BCSC population, but does not affect primary tumor growth in animal experiments.